Rhinomed (ASX:RNO) Common Stock : A$77.65 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Common Stock?

Rhinomed's quarterly common stock stayed the same from Jun. 2022 (A$77.65 Mil) to Dec. 2022 (A$77.65 Mil) and stayed the same from Dec. 2022 (A$77.65 Mil) to Jun. 2023 (A$77.65 Mil).

Rhinomed's annual common stock increased from Jun. 2021 (A$71.27 Mil) to Jun. 2022 (A$77.65 Mil) but then stayed the same from Jun. 2022 (A$77.65 Mil) to Jun. 2023 (A$77.65 Mil).

Rhinomed Common Stock Historical Data

The historical data trend for Rhinomed's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Common Stock Chart

Rhinomed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

59.24

71.27

77.65

Rhinomed Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Common Stock	Get a 7-Day Free Trial															71.27	72.99	77.65	77.65	77.65

Rhinomed Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Rhinomed (ASX:RNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

RHNMF:USA

Address

132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121

Website

https://www.rhinomed.global

Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines